Patients receiving radium‐223 experience lower rates of fracture, bone pain, and spinal cord compression.44 Enzalutamide is an androgen receptor inhibitor which has been shown to slow disease progression, delay chemotherapy administration, and improve overall survival in men with mCRPC.45 Sipuleucel‐T is an immunotherapy approved by the FDA in 2010 for the management of mCRPC that uses the patient's own cells to stimulate an immune response to prostate acid phosphatase and in turn prostate tumor cells. Here, AR is linked to prostate neoplasm.